Sitagliptin: the world’s first DPP-4 inhibitor
https://doi.org/10.21518/2079-701X-2019-4-14-19
Abstract
The prevalence of T2D is steadily increasing annually, which resulted in an active search for a way to control the disease. The last decade has seen a rise in the number of new groups of glucose-lowering drugs, which not only proved effective in the management of hyperglycemia and safe against hypoglycemia, but also joined the ranks of the drugs of the first-line therapy. Among them is incretin-active agents - type 4 dipeptidyl peptidases inhibitors (IDPP-4, glyptines). Sitagliptin was the world's first approved IDPP-4, and began to be used successfully in Russia since 2007. The review presents data on the efficacy, safety (including cardiac safety) of sitagliptin use and accumulated experience of its use in the treatment of patients with type 2 diabetes.
About the Authors
N. A. Petunina
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Petunina Nina Aleksandrovna - Dr. of Sci. (Med.), Professor, Head of Chair for Endocrinology, Clinical Medicine Institute, Federal State Autonomous Educational Institute of Higher Education.
Moscow, 119991, Trubetskaya St., 8, Bldg. 2, Work Phone: 8-495-530-32-16, eLibrary SPIN-code 97843616
E. V. Goncharova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Goncharova Ekaterina Valerievna - Cand. of Sci. (Med.), Assistant Professor of Chair for Endocrinology, Clinical Medicine Institute, Federal State Autonomous Educational Institute of Higher Education.
Moscow, 119991, Trubetskaya St., 8, Bldg. 2, Work Phone: 8-495-530-33-13, eLibrary SPIN-code 7148-4669
M. E. Telnova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Telnova Milena Eduardovna - Cand. of Sci. (Med.), Assistant Professor of Chair for Endocrinology, Clinical Medicine Institute, Federal State Autonomous Educational Institute of Higher Education.
Moscow, 119991, Trubetskaya St., 8, Bldg. 2, Work Phone: 8-495-530-33-13, eLibrary SPIN-code 1007-4617
L. V. Trukhina
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Trukhina Lyubov Valentinovna - Cand. of Sci. (Med.), Assistant Professor of Chair for Endocrinology, Clinical Medicine Institute, Federal State Autonomous Educational Institute of Higher Education.
Moscow, 119991, Trubetskaya St., 8, Bldg. 2, Work Phone: 8-495-530-33-13, eLibrary SPIN-code 2388-3053
N. S. Martirosyan
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Martirosyan Narine Stepanovna - Cand. of Sci. (Med.), Assistant Professor of Chair for Endocrinology, Clinical Medicine Institute, Federal State Autonomous Educational Institute of Higher Education.
Moscow, 119991, Trubetskaya St., 8, Bldg. 2, Work Phone: 8-495-530-33-13, eLibrary SPIN-code 1893-8030
References
1. Diabetes Atlas 8ed. international Diabetes Federation, 2017. Online version of IDF Diabetes Atlas. www.diabetesatlas.org.
2. Algorithms of Specialized Medical Care for Diab etes Mellitus Patients. Under the editorship of i.i. Dedov, M.V. Shestakov, A.Yu. Mayorov, issue 8. Sakhamy Diabet. 2017;20(1S):1-112. (in Russ).
3. Lankas G.R., Leiting B., Roy R.S., Eiermann GJ., Beconi M.G., Biftu T. et al. Dipeptidyl peptidase iV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes. 2005;54:2988-2994.
4. Petunina N.A., Goncharova E.V., Potapova S.A. Cardiovascular safety of glyptins: focus on alogliptin. Meditsinskij Sovet. 2017;3:32-37. (in Russ).
5. Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes preclinical biology and mechanisms of action. Diabetes Care. 2007;30:1335-1343.
6. Lamers D., Famulla S., Wronkowitz N., Hartwig S., Lehr S., Ouwens D.M. et aL Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes. 2011;60:1917-1925.
7. Ruter J., Hoffmann T., Demuth H.U., Moschansky P, Klapp B.F., Hildebrandt M. Evidence for an interaction between leptin, T cell costimulatory antigens CD28, CTLA-4 and CD26 (dipeptidyl peptidase iV) in BCG-induced immune responses of leptin- and leptin receptor-deficient mice. Biol Chem. 2004;385:537-541.
8. Aso Y., Terasawa T., Kato K., Jojima T., Suzuki K., iijima T., Kawagoe Y., Mikami S., Kubota Y., inukai T., Kasai K. The serum level of soluble CD26/dipeptidyl peptidase 4 increases in response to acute hyperglycemia after an oral glucose load in healthy subjects: association with high-molecular weight adiponectin and hepatic enzymes. Transl Res. 2013;162:309-316.
9. Petunina N.A., Trukhina L. V., Goncharova E.V. Role of vildagliptin in optimizing glycemic control. Spravochnik Poliklini-cheskogo Vracha. 2012;09:46-49. (In Russ).
10. Bergman AJ., Stevens C., Zhou Y., Yi B., Laethem M. , De Smet M. et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers. Clinical Therapeutics. 2O06 January; 28(1):55-72.
11. Herman G.A., Bergman A., Stevens C., Katy P.,Yi B., Zhao P. et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9.
12. Miller S., St Onge E.L. Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Ann Pharmacother. 2006 Jul-Aug;40(7-8):1336-43.
13. Petunina N.A., Goncharova E.V, Terekhova A.L. Diabetes Management. A new era of self-control: identifying trends and patterns of glyce-mia. Sakharny Diabet. 2017;20(6):441-448. (In Russ).
14. Chan J.C., Scott R., Arjona Ferreira J.C., Sheng D., Gonzalez E., Davies MJ. et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab. 2008 Jul;10(7):545-55.
15. Scott R., Morgan G., Zimmer Z. Lam R.L.H., O’Neill E.A., Kauffman K.D. et al. A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study. Diabetes Obes Metab. 2018;1-9.
16. Gomez N., Touihri K., Matheeussen V., Mendes Da Costa A., Mahmoudabady M., Mathieu M. et al. Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur J Heart Fail. 2012;14(1):14-21.
17. Read P.A., Khan F.Z., Heck P.M., Hoole S.P., Dutka D.P. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging. 2010;3(2):195-201.
18. Hibuse T., Maeda N., Kishida K., Kimura T., Minami T., Takeshita E. et al. A pilot 3-month sit-agliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus - a randomized controlled trial START-J study. Cardiovasc Diabetol. 2014;13:96.
19. Eurich D.T., Weir D.L., Simpson S.H., Senthilselvan A., McAlister F.A. Risk of new-onset heart failure in patients using sitagliptin: a population-based cohort study. Diabet Med. 2016 May;33(5):621-30.
20. Nakamura K., Oe H., Kihara H., Shimada K., Fukuda S., Watanabe K., Takagi T. et al. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study. Cardiovasc Diabetol. 2014;13:110.
21. Leibovitz E., Gottlieb S., Goldenberg I., Gevrielov-Yusim N., Matetzky S., Gavish D. Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS). Cardiovasc Diabetol. 2013;12:53.
22. Green J.B., Bethel M.A., Armstrong P. W., Buse J.B., Engel S.S. et al.Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373:232-242.
23. Engel S.S., Golm G.T., Shapiro D., Davies MJ., Kaufman K.D., Goldstein BJ. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol. 2013;12:3.
24. Shestakova M.V. Experience in using sitagliptin (the first DPP-4 inhibitor) in the treatment of type 2 diabetes in the Russian Federation: the results of the observational Dia-Da program. Sakharny Diabet. 2010;3:57-60. (In Russ).
25. Kim S.S., Kim I.Ch., Lee K.D., Park CH.H., Kim I.I., Li YS. et al. Efficacy and safety of the fixed combination of sitagliptin / metformin compared with glimepiride in patients with type 2 diabetes: a multicentre, randomized, double-blind study. Endokrinologia: Novosti, Mnenia, Obuchenie. 2017;4:64-78. (In Russ).
26. Perez-Monteverde A., Seck T., Xu L., Lee M.A., Sisk C.M., Williams-Herman D.E. et al. Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naive patients with type 2 diabetes. Int J Clin Pract. 2011 Sep;65(9):930-8.
27. Reasner C., Olansky L., Seck T.L. et al. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 2011;13:644-652.
Review
For citations:
Petunina NA, Goncharova EV, Telnova ME, Trukhina LV, Martirosyan NS. Sitagliptin: the world’s first DPP-4 inhibitor. Meditsinskiy sovet = Medical Council. 2019;(4):14-19. (In Russ.) https://doi.org/10.21518/2079-701X-2019-4-14-19
Views:
886
Email this article 